| Literature DB >> 29581790 |
Chen-Yang Tao1, Wei-Ren Liu1, Lei Jin1, Zheng Tang1, Meng-Xin Tian1, Xi-Fei Jiang1, Han Wang1, Pei-Yun Zhou1, Yuan Fang1, Zhen-Bin Ding1, Yuan-Fei Peng1, Zhi Dai1, Shuang-Jian Qiu1, Jian Zhou1,2, Jia Fan1,2, Ying-Hong Shi1.
Abstract
Aims: To compare the long-term prognosis of younger and elderly patients with combined hepatocellular-cholangiocarcinoma (CHC) who underwent curative resection between 1993 and 2014 at our center.Entities:
Keywords: Combined Hepatocellular-Cholangiocarcinoma; Hepatic resection; Propensity score matching; age
Year: 2018 PMID: 29581790 PMCID: PMC5868178 DOI: 10.7150/jca.23921
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Comparison of Demographic Data and Outcomes Between Younger (≤60 Years of Age) and Elderly (>60 Years of Age) Patients With CHC
| Total | Younger patients | Elderly patients | P value | |
|---|---|---|---|---|
| Age (yrs.) | 52.4±8.7 | 47.4±8.7 | 67.7±4.9 | <0.001 |
| Gender: Male | 161 (75.6%) | 123 (76.4%) | 38 (73.1%) | 0.682 |
| HBV: Positive | 159 (74.6%) | 135 (83.9%) | 24 (46.2%) | <0.001 |
| HCV: Positive | 5 (2.3%) | 3 (1.9%) | 2 (3.8%) | 0.597 |
| A | 202 (94.8%) | 156 (96.9%) | 46 (88.5%) | 0.027 |
| B | 11 (5.2%) | 5 (3.1%) | 6 (11.5%) | |
| ≤20 | 99 (46.5%) | 76 (47.2%) | 23 (44.2%) | 0.622 |
| >20 | 114 (53.5%) | 85 (52.8%) | 29 (55.8%) | |
| ≤5 | 174 (81.7%) | 132 (82%) | 42 (80.8%) | 0.911 |
| >5 | 39 (18.3%) | 29 (18%) | 10 (19.2%) | |
| ≤37 | 140 (65.7%) | 106 (65.8%) | 34 (65.4%) | 0.862 |
| >37 | 73 (34.3%) | 55 (34.2%) | 18 (34.6%) | |
| TB (μmol/L): >17 | 41 (18.8%) | 29 (17.6%) | 12 (22.6%) | 0.674 |
| ALB (g/L): <40 | 73 (33.5%) | 45 (27.3%) | 28 (52.8%) | 0.001 |
| ALT (U/L): >35 | 90 (41.3%) | 72 (43.6%) | 18 (34%) | 0.213 |
| GGT (U/L): >40 | 155 (71.1%) | 114 (69.1%) | 41 (77.4%) | 0.248 |
| Ascites (ml) | ||||
| No | 193 (90.6%) | 151 (93.8%) | 42 (80.8%) | 0.011 |
| Yes | 20 (9.4%) | 10 (6.2%) | 10 (19.2%) | |
| Single | 159 (74.6%) | 118 (73.3%) | 41 (78.8%) | 0.423 |
| Multiple | 54 (25.4%) | 43 (26.7%) | 11 (21.2%) | |
| Tumor Diameter (cm) | 6.4 (3.5-8.0) | 6.4 (3.5-8.0) | 6.4 (3.3-7.7) | 0.852 |
| No | 200 (93.9%) | 151 (93.8%) | 49 (94.2%) | 1.000 |
| Yes | 13 (6.1%) | 10 (6.2%) | 3 (5.8%) | |
| No | 167 (78.4%) | 124 (77%) | 43 (82.7%) | 0.309 |
| Yes | 46 (21.6%) | 37 (23%) | 9 (17.3%) | |
| No | 188 (88.3%) | 147 (91.3%) | 41 (78.8%) | 0.024 |
| Yes | 25 (11.7%) | 14 (8.7%) | 11 (21.2%) | |
| No | 206 (96.7%) | 156 (96.9%) | 50 (96.2%) | 0.678 |
| Yes | 7 (3.3%) | 5 (3.1%) | 2 (3.8%) |
Prognostic Analysis of Overall Survival and Disease-free Survival Before Propensity Score Matching
| Overall survival | Disease-free survival | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | ||||||||
| Variables | HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P | |||
| Age (yrs.): >60 vs ≤60 | 1.326 (0.869-2.023) | 0.190 | 1.306 (0.795-2.145) | 0.292 | |||||||
| Gender: Male vs Female | 1.507 (0.955-2.378) | 0.078 | 1.501 (0.917-2.456) | 0.106 | 1.928 (1.101-3.375) | 0.022 | 2.453 (1.339-4.495) | 0.004 | |||
| Child-Pugh Class: B vs A | 1.942 (0.940-4.015) | 0.073 | 1.523 (0.691-3.357) | 0.296 | 0.846 (0.267-2.688) | 0.777 | |||||
| Comorbid illness: Yes vs No | 1.336 (0.921-1.937) | 0.127 | 1.083 (0.706-1.661) | 0.715 | |||||||
| HBV: Positive vs Negative | 0.962 (0.644-1.437) | 0.849 | 1.477 (0.868-2.512) | 0.150 | |||||||
| HCV: Positive vs Negative | 2.502 (0.784-7.983) | 0.121 | 0.818 (0.113-5.907) | 0.842 | |||||||
| AFP (ng/ml): >20 vs ≤20 | 0.879 (0.614-1.259) | 0.482 | 0.832 (0.544-1.272) | 0.396 | |||||||
| CEA (ng/ml): >5 vs ≤5 | 1.597 (1.050-2.428) | 0.029 | 1.628 (1.045-2.538) | 0.031 | 0.825 (0.465-1.464) | 0.512 | |||||
| CA199 (U/ml): >37 vs ≤37 | 1.514 (1.053-2.176) | 0.025 | 1.117 (0.763-1.635) | 0.571 | 1.004 (0.639-1.578) | 0.985 | |||||
| TB (μmol/L): >17 vs ≤17 | 0.938 (0.599-1.471) | 0.781 | 1.000 (0.593-1.685) | 1.000 | |||||||
| ALB (g/L): <40 vs ≥40 | 1.318 (0.909-1.911) | 0.145 | 1.213 (0.771-1.909) | 0.405 | |||||||
| ALT (U/L): >35 vs ≤35 | 1.285 (0.900-1.834) | 0.168 | 1.644 (1.074-2.516) | 0.022 | 1.394 (0.896-2.169) | 0.141 | |||||
| GGT (U/L): >40 vs ≤40 | 2.711 (1.700-4.323) | <0.001 | 2.069 (1.228-3.485) | 0.006 | 1.866 (1.125-3.095) | 0.016 | 1.367 (0.801-2.332) | 0.251 | |||
| Ascites: Yes vs No | 1.410 (0.809-2.458) | 0.226 | 1.799 (0.971-3.333) | 0.062 | 0.501 (0.187-1.342) | 0.169 | |||||
| Tumor Nodularity: Multiple vs Single | 1.557 (1.055-2.298) | 0.026 | 1.484 (0.986-2.233) | 0.059 | 1.224 (0.758-1.976) | 0.408 | |||||
| Tumor Diameter (cm): >5 vs ≤5 | 2.424 (1.665-3.530) | <0.001 | 1.320 (0.870-2.002) | 0.192 | 1.429 (0.929-2.196) | 0.104 | |||||
| Macroscopic VI: Yes vs No | 3.805 (2.070-6.993) | <0.001 | 3.211 (1.765-5.841) | <0.001 | 5.089 (2.371-10.922) | <0.001 | 3.602 (1.647-7.879) | 0.001 | |||
| Microscopic VI: Yes vs No | 1.437 (0.944-2.188) | 0.090 | 1.542 (0.994-2.394) | 0.053 | 1.192 (0.708-2.007) | 0.508 | |||||
| Lymphoid Metastases: Yes vs No | 2.822 (1.699-4.686) | <0.001 | 2.481 (1.358-4.530) | 0.003 | 2.454 (1.342-4.486) | 0.004 | 3.297 (1.710-6.357) | <0.001 | |||
| Extrahepatic Metastases: Yes vs No | 11.186 (4.900-25.536) | <0.001 | 5.060 (2.026-12.639) | 0.001 | 2.987 (0.710-12.566) | 0.135 | |||||
Characteristics of Patients before and after Propensity Score Matching
| Before Matching | After Matching | ||||||
|---|---|---|---|---|---|---|---|
| Younger patients (n=161) | Elderly patients | Std. Mean | Younger patients | Elderly patients | Std. Mean | ||
| Age (yrs.) | 47.6±8.6 | 67.7±5.0 | 2.872 | 47.0±8.2 | 67.5±5.1 | 3.015 | |
| Gender | |||||||
| Female | 38 (23.6%) | 14 (26.9%) | 0.076 | 8 (17.4%) | 8 (17.4%) | 0.000 | |
| Male | 123 (76.4%) | 38 (73.1%) | 0.076 | 38 (82.6%) | 38 (82.6%) | 0.000 | |
| CEA (ng/ml): | |||||||
| >5 | 132 (82%) | 42 (80.8%) | 0.031 | 39 (84.8%) | 39 (84.8%) | 0.000 | |
| ≤5 | 29 (18%) | 10 (19.2%) | 0.031 | 7 (15.2%) | 7 (15.2%) | 0.000 | |
| GGT (U/L) | |||||||
| >40 | 50 (31.1%) | 12 (23.1%) | 0.180 | 11 (23.9%) | 11 (23.9%) | 0.000 | |
| ≤40 | 111 (68.9%) | 40 (76.9%) | 0.180 | 35 (76.1%) | 35 (76.1%) | 0.000 | |
| Macroscopic VI | |||||||
| No | 151 (93.8%) | 49 (94.2%) | 0.019 | 44 (95.7%) | 44 (95.7%) | 0.000 | |
| Yes | 10 (6.2%) | 3 (5.8%) | 0.019 | 2 (4.3%) | 2 (4.3%) | 0.000 | |
| Lymphoid Metastases | |||||||
| No | 147 (91.3%) | 41 (78.8%) | 0.355 | 39 (84.8%) | 39 (84.8%) | 0.000 | |
| Yes | 14 (8.7%) | 11 (21.2%) | 0.355 | 7 (15.2%) | 7 (15.2%) | 0.000 | |
| Extrahepatic Metastases | |||||||
| No | 156 (96.9%) | 50 (96.2%) | 0.040 | 45 (97.8%) | 45 (97.8%) | 0.000 | |
| Yes | 5 (3.1%) | 2 (3.8%) | 0.040 | 1 (2.2%) | 1 (2.2%) | 0.000 | |
Note: Values in n (%), mean ± standard deviation.Std. mean difference: standardized mean difference